Technical Analysis for PRME - Prime Medicine, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.43 | 2.91% | 0.13 |
PRME closed up 2.91 percent on Friday, April 26, 2024, on 83 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 2.91% | |
| New 52 Week Low | Weakness | 2.91% | |
| Stochastic Reached Oversold | Weakness | 2.91% | |
| Wide Bands | Range Expansion | 2.91% | |
| Gapped Down | Weakness | 2.91% | |
| Oversold Stochastic | Weakness | 2.91% | |
| Wide Bands | Range Expansion | -5.85% | |
| Oversold Stochastic | Weakness | -5.85% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 10 hours ago |
| Up 5% | about 10 hours ago |
| 60 Minute Opening Range Breakout | about 11 hours ago |
| Up 3% | about 14 hours ago |
| Up 2% | about 14 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.195 |
| 52 Week Low | 4.11 |
| Average Volume | 775,811 |
| 200-Day Moving Average | 8.86 |
| 50-Day Moving Average | 6.89 |
| 20-Day Moving Average | 5.39 |
| 10-Day Moving Average | 4.77 |
| Average True Range | 0.45 |
| RSI (14) | 28.57 |
| ADX | 40.53 |
| +DI | 14.88 |
| -DI | 37.56 |
| Chandelier Exit (Long, 3 ATRs) | 5.72 |
| Chandelier Exit (Short, 3 ATRs) | 5.45 |
| Upper Bollinger Bands | 6.80 |
| Lower Bollinger Band | 3.99 |
| Percent B (%b) | 0.15 |
| BandWidth | 51.99 |
| MACD Line | -0.67 |
| MACD Signal Line | -0.63 |
| MACD Histogram | -0.0459 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.16 | ||||
| Resistance 3 (R3) | 5.15 | 4.90 | 5.04 | ||
| Resistance 2 (R2) | 4.90 | 4.71 | 4.91 | 5.00 | |
| Resistance 1 (R1) | 4.66 | 4.60 | 4.78 | 4.67 | 4.96 |
| Pivot Point | 4.41 | 4.41 | 4.47 | 4.41 | 4.41 |
| Support 1 (S1) | 4.17 | 4.22 | 4.29 | 4.18 | 3.89 |
| Support 2 (S2) | 3.92 | 4.11 | 3.92 | 3.85 | |
| Support 3 (S3) | 3.68 | 3.92 | 3.81 | ||
| Support 4 (S4) | 3.69 |
